Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Central Nervous System Neoplasm”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00085540
What this trial is testing

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

Who this might be right for
Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell Glioblastoma+2 more
National Cancer Institute (NCI) 50
Large-scale testing (Phase 3)Study completedNCT00005805
What this trial is testing

St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer

Who this might be right for
Chronic Myeloproliferative DisordersFatigueLeukemia+5 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT01257594
What this trial is testing

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Who this might be right for
Brain Cancer
Andrew B Lassman, MD 22
Testing effectiveness (Phase 2)Ended earlyNCT00554775
What this trial is testing

WBRT & Erlotinib in Advanced NSCLC and Brain Metastases

Who this might be right for
Lung CancerMetastatic Cancer
University College, London 80
Early research (Phase 1)Study completedNCT00003395
What this trial is testing

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00617539
What this trial is testing

Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases

Who this might be right for
Breast CancerMetastatic Cancer
University of California, San Francisco 30
Not applicableStudy completedNCT00082836
What this trial is testing

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT02867592
What this trial is testing

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Who this might be right for
Adrenal Cortical CarcinomaAlveolar Soft Part SarcomaCentral Nervous System Neoplasm+41 more
National Cancer Institute (NCI) 109
Early research (Phase 1)Looking for participantsNCT06815432
What this trial is testing

GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma

Who this might be right for
Glioblastoma Multiforme of Brain
Baylor College of Medicine 27
Testing effectiveness (Phase 2)Study completedNCT01478178
What this trial is testing

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

Who this might be right for
GliomaGlioblastomaGlioblastoma Multiforme+2 more
Kintara Therapeutics, Inc. 55
Testing effectiveness (Phase 2)Study completedNCT00672243
What this trial is testing

Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme

Who this might be right for
GlioblastomaGliosarcoma
Duke University 32
Early research (Phase 1)Study completedNCT00501748
What this trial is testing

Safety and Tolerability of Rituximab in Neuromyelitis Optica

Who this might be right for
Neuromyelitis Optica
University of California, San Francisco 20
Testing effectiveness (Phase 2)Study completedNCT02301364
What this trial is testing

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Who this might be right for
LymphomaPrimary Central Nervous System LymphomaRecurrent/Refractory Secondary Central Nervous System Lymphoma
Memorial Sloan Kettering Cancer Center 4
Very early researchNot Yet RecruitingNCT07784985
What this trial is testing

NST-628 in Recurrent Grade 4 Glioma

Who this might be right for
Glioma, Recurrent High GradeGrade 4 Malignant Glioma
Nader Sanai 12
Early research (Phase 1)Study completedNCT02171260
What this trial is testing

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

Who this might be right for
PediatricsSolid Tumors
Eisai Inc. 23
Testing effectiveness (Phase 2)UnknownNCT00005084
What this trial is testing

Magnetic Resonance Imaging in Treating Children With Progressive Low-Grade Astrocytoma

Who this might be right for
Brain and Central Nervous System Tumors
Jonsson Comprehensive Cancer Center 24
Testing effectiveness (Phase 2)Study completedNCT01967810
What this trial is testing

ANG1005 in Patients With Recurrent High-Grade Glioma

Who this might be right for
GliomaGlioblastomaBrain Tumor, Recurrent
Angiochem Inc 73
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Early research (Phase 1)Study completedNCT01048008
What this trial is testing

Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer

Who this might be right for
Advanced CancerBrain Involvement
DEKK-TEC, Inc. 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT02981940
What this trial is testing

Abemaciclib in Recurrent Glioblastoma

Who this might be right for
Glioblastoma
Dana-Farber Cancer Institute 45
Next Page